Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 32 | 2024 | 465 | 7.240 |
Why?
|
| Health Policy | 7 | 2024 | 188 | 2.610 |
Why?
|
| Quality-Adjusted Life Years | 20 | 2024 | 144 | 2.510 |
Why?
|
| Medicare Part C | 3 | 2022 | 7 | 2.470 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 436 | 2.430 |
Why?
|
| Research Design | 4 | 2020 | 591 | 1.570 |
Why?
|
| Models, Economic | 5 | 2020 | 62 | 1.520 |
Why?
|
| Policy Making | 3 | 2020 | 63 | 1.390 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 435 | 1.350 |
Why?
|
| Obesity | 6 | 2024 | 972 | 1.330 |
Why?
|
| Anti-Obesity Agents | 2 | 2024 | 13 | 1.150 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 319 | 1.110 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 58 | 1.100 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 305 | 1.100 |
Why?
|
| United States | 20 | 2024 | 7080 | 1.090 |
Why?
|
| Pandemics | 3 | 2020 | 778 | 1.030 |
Why?
|
| Health Care Costs | 7 | 2023 | 236 | 1.010 |
Why?
|
| Bariatric Surgery | 2 | 2018 | 198 | 1.000 |
Why?
|
| Obesity, Morbid | 2 | 2018 | 239 | 0.990 |
Why?
|
| Decision Making | 4 | 2019 | 669 | 0.980 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 419 | 0.960 |
Why?
|
| Deprescriptions | 1 | 2024 | 6 | 0.950 |
Why?
|
| Mass Screening | 3 | 2022 | 645 | 0.940 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2024 | 35 | 0.920 |
Why?
|
| Global Health | 4 | 2021 | 193 | 0.900 |
Why?
|
| Public Policy | 1 | 2024 | 52 | 0.900 |
Why?
|
| Checklist | 2 | 2023 | 61 | 0.870 |
Why?
|
| Humans | 51 | 2024 | 89768 | 0.850 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1735 | 0.850 |
Why?
|
| Weight Loss | 1 | 2024 | 233 | 0.820 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 715 | 0.820 |
Why?
|
| Cost of Illness | 2 | 2020 | 148 | 0.790 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 296 | 0.790 |
Why?
|
| Nutrition Policy | 3 | 2023 | 13 | 0.780 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 264 | 0.770 |
Why?
|
| Health Facilities | 1 | 2021 | 39 | 0.750 |
Why?
|
| Communication | 1 | 2024 | 461 | 0.720 |
Why?
|
| Critical Pathways | 1 | 2020 | 37 | 0.710 |
Why?
|
| Quarantine | 1 | 2020 | 8 | 0.700 |
Why?
|
| Quality of Life | 4 | 2024 | 1674 | 0.700 |
Why?
|
| Meat Products | 1 | 2019 | 7 | 0.680 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 149 | 0.680 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 744 | 0.670 |
Why?
|
| Neoplasms | 4 | 2023 | 3062 | 0.660 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 170 | 0.660 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 165 | 0.650 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 624 | 0.640 |
Why?
|
| Population Health | 1 | 2019 | 33 | 0.630 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 53 | 0.620 |
Why?
|
| Publications | 1 | 2018 | 27 | 0.600 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 48 | 0.600 |
Why?
|
| Prostate-Specific Antigen | 3 | 2024 | 338 | 0.550 |
Why?
|
| Quality Improvement | 1 | 2020 | 457 | 0.530 |
Why?
|
| Motivation | 1 | 2019 | 296 | 0.520 |
Why?
|
| Uncertainty | 4 | 2023 | 76 | 0.510 |
Why?
|
| Insurance Coverage | 3 | 2023 | 123 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 260 | 0.490 |
Why?
|
| Registries | 5 | 2024 | 792 | 0.460 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 111 | 0.460 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 364 | 0.450 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 683 | 0.450 |
Why?
|
| Health Expenditures | 4 | 2024 | 90 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 607 | 0.420 |
Why?
|
| Hepatitis C | 1 | 2014 | 174 | 0.410 |
Why?
|
| Male | 12 | 2024 | 42578 | 0.400 |
Why?
|
| Developing Countries | 3 | 2023 | 80 | 0.390 |
Why?
|
| Aged | 8 | 2024 | 19209 | 0.370 |
Why?
|
| Health Priorities | 3 | 2020 | 22 | 0.370 |
Why?
|
| Antiviral Agents | 1 | 2014 | 482 | 0.370 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2020 | 27 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1180 | 0.340 |
Why?
|
| Young Adult | 6 | 2024 | 6386 | 0.330 |
Why?
|
| Female | 12 | 2024 | 46491 | 0.330 |
Why?
|
| Orphan Drug Production | 2 | 2019 | 4 | 0.330 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1729 | 0.320 |
Why?
|
| Adult | 9 | 2024 | 26762 | 0.320 |
Why?
|
| Middle Aged | 9 | 2024 | 26076 | 0.280 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2367 | 0.260 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3021 | 0.260 |
Why?
|
| Adolescent | 4 | 2024 | 9325 | 0.230 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 23 | 0.220 |
Why?
|
| Health Status | 2 | 2024 | 371 | 0.220 |
Why?
|
| Medicare Part D | 1 | 2023 | 10 | 0.220 |
Why?
|
| Efficiency | 1 | 2023 | 40 | 0.210 |
Why?
|
| Vaccination | 2 | 2022 | 278 | 0.210 |
Why?
|
| Incidence | 2 | 2019 | 1598 | 0.210 |
Why?
|
| Risk Factors | 3 | 2023 | 5538 | 0.210 |
Why?
|
| Drug Costs | 2 | 2020 | 63 | 0.200 |
Why?
|
| Food Labeling | 1 | 2021 | 8 | 0.190 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2020 | 7 | 0.180 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2020 | 13 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1083 | 0.180 |
Why?
|
| Marijuana Abuse | 1 | 2020 | 26 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2021 | 91 | 0.180 |
Why?
|
| Age Factors | 2 | 2022 | 1879 | 0.180 |
Why?
|
| Social Conditions | 1 | 2020 | 8 | 0.180 |
Why?
|
| Actuarial Analysis | 1 | 2020 | 66 | 0.180 |
Why?
|
| Social Control, Formal | 1 | 2020 | 12 | 0.180 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 5 | 0.180 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 153 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 262 | 0.170 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2019 | 3 | 0.170 |
Why?
|
| Fear | 1 | 2020 | 79 | 0.170 |
Why?
|
| Cardiology | 1 | 2021 | 115 | 0.170 |
Why?
|
| Markov Chains | 3 | 2014 | 127 | 0.170 |
Why?
|
| Health Behavior | 1 | 2021 | 185 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2020 | 860 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2024 | 1101 | 0.170 |
Why?
|
| Child | 2 | 2024 | 7231 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 6777 | 0.160 |
Why?
|
| Professional Review Organizations | 1 | 2018 | 1 | 0.160 |
Why?
|
| Probability | 1 | 2019 | 350 | 0.160 |
Why?
|
| Cost Sharing | 1 | 2018 | 17 | 0.150 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 2 | 0.150 |
Why?
|
| Life Tables | 1 | 2018 | 47 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 326 | 0.150 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 66 | 0.150 |
Why?
|
| Bibliometrics | 1 | 2018 | 37 | 0.150 |
Why?
|
| Consensus | 1 | 2019 | 365 | 0.150 |
Why?
|
| Income | 1 | 2018 | 85 | 0.150 |
Why?
|
| Research | 1 | 2018 | 251 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2019 | 375 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 237 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 141 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8240 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 236 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 71 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 848 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2019 | 1496 | 0.120 |
Why?
|
| Egypt | 1 | 2014 | 13 | 0.120 |
Why?
|
| Uridine Monophosphate | 1 | 2014 | 4 | 0.120 |
Why?
|
| Sofosbuvir | 1 | 2014 | 9 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2648 | 0.120 |
Why?
|
| Decision Trees | 1 | 2014 | 59 | 0.120 |
Why?
|
| Ribavirin | 1 | 2014 | 40 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2018 | 775 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 402 | 0.120 |
Why?
|
| Interferons | 1 | 2014 | 127 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 374 | 0.110 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 8 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1134 | 0.110 |
Why?
|
| Laser Coagulation | 1 | 2013 | 55 | 0.100 |
Why?
|
| Macular Edema | 1 | 2013 | 50 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2019 | 2886 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 783 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 919 | 0.100 |
Why?
|
| Cloprostenol | 1 | 2012 | 1 | 0.100 |
Why?
|
| Trabeculectomy | 1 | 2012 | 4 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 91 | 0.100 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 19 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 293 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2013 | 357 | 0.090 |
Why?
|
| Prevalence | 1 | 2014 | 1249 | 0.090 |
Why?
|
| Disease Progression | 1 | 2014 | 1466 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2012 | 148 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 251 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2674 | 0.080 |
Why?
|
| Time Factors | 1 | 2017 | 5349 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2024 | 164 | 0.050 |
Why?
|
| Energy Intake | 1 | 2023 | 99 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2022 | 67 | 0.050 |
Why?
|
| Dietary Sugars | 1 | 2021 | 8 | 0.050 |
Why?
|
| British Columbia | 1 | 2020 | 8 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 70 | 0.050 |
Why?
|
| Biopsy | 1 | 2024 | 1184 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 444 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 35 | 0.040 |
Why?
|
| China | 1 | 2020 | 235 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 109 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2020 | 72 | 0.040 |
Why?
|
| Health Planning | 1 | 2018 | 17 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2020 | 194 | 0.040 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2018 | 10 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 140 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 508 | 0.040 |
Why?
|
| Health Services | 1 | 2018 | 57 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 72 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 902 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 10 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 32 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2018 | 139 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 312 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 871 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 493 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2018 | 352 | 0.030 |
Why?
|
| Ranibizumab | 1 | 2013 | 16 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2013 | 16 | 0.030 |
Why?
|
| Financing, Personal | 1 | 2013 | 21 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2013 | 73 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 3040 | 0.030 |
Why?
|
| Travoprost | 1 | 2012 | 1 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3468 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 268 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 405 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 140 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1704 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 952 | 0.020 |
Why?
|